{"id":"NCT00254982","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)","officialTitle":"An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I (\"High Need\") and GROUP II (\"Low Need\") Patients Suffering From Chronic Plaque Psoriasis (Psoriasis Vulgaris)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08","primaryCompletion":"2006-09","completion":"2006-09","firstPosted":"2005-11-17","resultsPosted":"2010-07-05","lastUpdate":"2015-10-12"},"enrollment":593,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Infliximab","otherNames":["Remicade","SCH 215596"]}],"arms":[{"label":"Group 1 (high-need)","type":"EXPERIMENTAL"},{"label":"Group II (low-need)","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multicenter, parallel-group comparison study of the efficacy, safety, and tolerability of infliximab therapy in adult patients suffering from chronic plaque psoriasis (psoriasis vulgaris). Patients will be assigned to GROUP I (\"high need\") or GROUP II (\"low-need\") by the investigator according to their previous psoriasis treatment.","primaryOutcome":{"measure":"Proportion of Participants Achieving a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score","timeFrame":"Baseline and Week 22","effectByArm":[{"arm":"Group 1 (High-need)","deltaMin":0.739,"sd":null},{"arm":"Group II (Low-need)","deltaMin":0.698,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":23},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":297},"commonTop":["NASOPHARYNGITIS","INFLUENZA LIKE ILLNESS","HEADACHE"]}}